⚠ Evidence warning: Clinical trials or other evidence do not support the claims that chanca piedra lowers uric acid and blood pressure in people and reduces gout flares. This page keeps it as a report of what people, websites or other media say.

Chanca Piedra for Uric Acid, Gout, and Hypertension

Uric Acid Gout and Hypertension — scientific infographic poster

Chanca Piedra (Phyllanthus niruri, with overlapping pharmacology in P. amarus and P. urinaria) is best known as a kidney-stone herb, but the same biochemistry that breaks calcium-oxalate aggregates also touches three other clinically connected pathologies: hyperuricemia, gout, and essential hypertension. This page traces the mechanistic threads — xanthine oxidase inhibition, angiotensin-converting enzyme inhibition, mild potassium-sparing diuresis, endothelial nitric-oxide effects — and reviews the clinical evidence that exists for each indication. The companion Kidney Stones (Benefits) page covers the stone-disruption mechanism; this page is about what happens to the rest of the patient's labs and blood pressure when they take Phyllanthus over months and years.

Table of Contents

Overview: Three Connected Pathologies

Hyperuricemia — a serum uric acid above roughly 6.8 mg/dL, the solubility limit at physiological pH and temperature — is the upstream lesion behind three downstream syndromes that show up in the same patients again and again:

These three pathologies share an upstream switch. Anything that lowers serum urate and improves urinary urate solubility addresses all three at once. Allopurinol and febuxostat do this pharmacologically by inhibiting xanthine oxidase. The mechanistic claim for Chanca Piedra is that it shares the same enzymatic target, plus a layer of angiotensin-converting enzyme inhibition and a layer of mild natriuresis — a combined profile that maps reasonably well onto the hyperuricemia-plus-hypertension phenotype that fills nephrology and rheumatology clinics. The rat study behind the target claim ranks the mechanisms differently: Murugaiyah and Chan concluded that the extract's effect "may be mainly due to its uricosuric action and partly through xanthine oxidase inhibition" — mainly more uric acid passed in the urine.

The strength of evidence varies sharply across the three indications. Kidney-stone protection has the best mechanistic and the most clinical support (covered in detail on the Kidney Stones page). Uric-acid lowering and xanthine-oxidase inhibition have solid pre-clinical and modest clinical data. Blood-pressure lowering has consistent small-trial signals but no modern Phase III randomized controlled trial. The rest of this page goes through each in turn.

Back to Table of Contents

Uric Acid Biology and Why It Matters

Uric acid is the end-product of purine catabolism in humans and the great apes. Most other mammals possess uricase, an enzyme that converts uric acid to the far more soluble allantoin; humans lost the functional gene roughly 15 million years ago. The plausible adaptive story is that uric acid functions as a low-grade antioxidant in the bloodstream, and a slightly higher baseline urate may have helped sodium retention during dietary salt scarcity on the African savannah. Whatever the reason, the consequence is that humans walk a narrow line: serum urate is high enough to be a useful antioxidant in early adulthood and low enough to stay below the precipitation threshold — unless modern Western diet, fructose load, alcohol, diuretic drugs, kidney function, or genetic variants in SLC2A9, ABCG2, SLC22A12 nudge the balance over the line.

The biosynthetic pathway from purine bases to uric acid runs through hypoxanthine and xanthine:

  1. Adenosine → inosine (via adenosine deaminase) → hypoxanthine (via purine nucleoside phosphorylase).
  2. Guanosine → guanine → xanthine (via guanine deaminase).
  3. Hypoxanthine → xanthine (via xanthine oxidase, XO).
  4. Xanthine → uric acid (via xanthine oxidase, again).

Xanthine oxidase catalyzes the final two oxidation steps. It is a molybdenum-and-iron-sulfur metalloflavoenzyme that exists in two interconvertible forms — the dehydrogenase (XDH) form, which transfers electrons to nicotinamide adenine dinucleotide (NAD+), and the oxidase (XO) form, which transfers electrons to molecular oxygen and generates superoxide and hydrogen peroxide as byproducts. The conversion from XDH to XO is driven by tissue inflammation and ischemia. This is why hyperuricemia is more than a precipitation problem — the same enzyme that produces excess urate also produces excess reactive oxygen species, contributing directly to endothelial dysfunction and vascular smooth-muscle oxidative stress. Inhibiting XO addresses both the urate load and the oxidative burden in one step.

Allopurinol — a hypoxanthine analog — is itself oxidized by XO to oxypurinol, which then binds the reduced enzyme tightly and inhibits it competitively. Febuxostat is a structurally unrelated non-purine inhibitor that binds the molybdenum-pterin pocket more selectively. Both drugs cut serum urate by 30-60% in most patients; both are first-line for chronic gout. The herbal-extract literature on xanthine oxidase inhibition is dominated by polyphenols — flavonoids (luteolin, apigenin, quercetin), tannins, and lignans — that occupy related parts of the same binding pocket with weaker but biologically meaningful Ki values.

The precipitation threshold matters for clinical decision-making. At normal body temperature and pH 7.4, monosodium urate solubility is roughly 6.8 mg/dL (about 400 μmol/L). In cooler peripheral joints (32-34°C), solubility drops further. In acid urine (pH < 5.5), the protonated uric-acid form predominates and its solubility falls to roughly 100 mg/L — an order of magnitude lower than urate. This is why simply alkalinizing the urine with potassium citrate or bicarbonate dramatically reduces uric-acid stone risk even without lowering total urate excretion. Phyllanthus extracts have weak urinary-alkalinizing activity in some preparations, but this is not their main mechanism.

Clinically, target serum urate in gout is <6.0 mg/dL (or <5.0 mg/dL with tophaceous disease) — both targets sit comfortably below the precipitation threshold to allow MSU crystal dissolution and tophus regression over time. Any intervention that pushes a patient from 8 to 6 mg/dL is doing real clinical work, even if it sounds like a modest percentage change.

Back to Table of Contents

Xanthine Oxidase Inhibition by Phyllanthus niruri

The xanthine-oxidase inhibitory activity of Phyllanthus extracts is one of the better-characterized pharmacologic properties of the genus, with both cell-free enzyme assays and animal hyperuricemia models converging on a consistent picture.

The pre-clinical picture is therefore: real XO inhibition, weaker than allopurinol on a per-milligram basis, alongside a uricosuric action that the rat work ranks as the main effect, plus claimed anti-inflammatory and antioxidant action. This is the platform on which the human clinical data — uneven but not absent — sits.

Back to Table of Contents

Gout — Acute and Chronic

The clinical literature on Phyllanthus in gout and hyperuricemia is sparse compared to the kidney-stone and hepatitis B virus (HBV) literature, but it is not empty. Key signals:

The honest summary: Phyllanthus has plausible, modestly supported, mechanistically defensible urate-lowering activity. Integrative practitioners place it in the toolkit for borderline hyperuricemia and as a long-term adjunct after standard urate-lowering therapy has reached target. It does not replace allopurinol or febuxostat for established gout.

Back to Table of Contents

Mechanism in Hypertension

The blood-pressure effects of Phyllanthus extracts have been characterized in isolated-vessel preparations, anesthetized-animal hemodynamics, and a small number of human pilot studies. Four mechanisms appear to contribute, none of them individually large but additively meaningful:

The combined profile — weak angiotensin-converting enzyme inhibition + mild vasorelaxation + mild potassium-sparing natriuresis + endothelial NO preservation — is closer to a thiazide-plus-angiotensin-converting-enzyme-inhibitor pharmacology than to any single drug class, although weaker on all axes. This explains why the clinical effects on blood pressure are real but modest, and why patients who respond tend to be those with hyperuricemia-associated hypertension (where the XO-and-NO axis matters) or salt-sensitive hypertension (where the natriuresis axis matters), rather than those with severe renovascular or end-stage hypertensive disease.

Back to Table of Contents

Clinical Studies in Blood Pressure

The human blood-pressure literature on Phyllanthus is small but encouragingly consistent in direction:

How practitioners use it: in stage-1 hypertension, particularly in people who also have hyperuricemia, kidney stones, or fatty liver, some practitioners describe a 3-month trial of standardized P. niruri 500-1000 mg/day as an adjunct or, in motivated people with mild disease, as a first-line trial before pharmacologic therapy. These protocols include home blood pressure and serum urate checks, and treat failure to reach target (typically <130/80 mmHg per current guidelines) as the point of moving to conventional drugs.

Back to Table of Contents

Synergy with Diet and Lifestyle

Hyperuricemia, gout, and uric-acid-driven hypertension are all profoundly diet-sensitive, and the largest gains from a Chanca Piedra trial come when the herb is layered on top of dietary changes that address the upstream drivers of urate production. The relevant levers:

A model practitioners describe: in a person with hyperuricemia + mild hypertension, a 3-month trial combining standardized P. niruri 1000 mg/day plus DASH diet plus fructose <25 g/day plus 3 L/day fluid plus 1000 mg/day vitamin C plus 2-3 cups coffee may produce a 1.5-2.5 mg/dL urate drop and a 10-15 mmHg systolic drop — comparable to starting one drug, and arguably with broader metabolic upside. If targets aren't reached, the patient and clinician have a clear basis for escalating to pharmacologic urate-lowering or antihypertensive therapy without abandoning the lifestyle gains.

Back to Table of Contents

Dosing and Duration

Dosing for the hyperuricemia, gout, and hypertension indications draws from a smaller and less standardized literature than the kidney-stone literature. Doses described in practitioner protocols:

For the full dosing matrix across all indications (kidney stones, hepatitis B, hepatoprotection) see the Forms, Dosing & Standardization page.

Back to Table of Contents

Cautions and Drug Interactions

The cautions for the uric-acid / gout / hypertension use pattern are slightly different from those for the kidney-stone or hepatitis B virus use pattern, mostly because the patient population overlaps heavily with people already taking cardiovascular and gout medications:

For the broader interaction profile (including cytochrome P450 3A4 substrates, anticoagulants, antidiabetics, immunosuppressants) see the Safety & Drug Interactions page.

Back to Table of Contents

Key Research Papers

  1. Murugaiyah V, Chan KL. Mechanisms of antihyperuricemic effect of Phyllanthus niruri and its lignan constituents. J Ethnopharmacol 2009;124(2):233-9. — PubMed PMID: 19397979 · doi:10.1016/j.jep.2009.04.026
  2. Murugaiyah V, Chan KL. Antihyperuricemic lignans from the leaves of Phyllanthus niruri. Planta Med 2006;72(14):1262-7. — PubMed PMID: 16953466 · doi:10.1055/s-2006-947224
  3. Patel JR, Tripathi P, Sharma V, Chauhan NS, Dixit VK. Phyllanthus amarus: ethnomedicinal uses, phytochemistry and pharmacology: a review. J Ethnopharmacol 2011;138(2):286-313. — PubMed PMID: 21982793 · doi:10.1016/j.jep.2011.09.040
  4. Bagalkotkar G, Sagineedu SR, Saad MS, Stanslas J. Phytochemicals from Phyllanthus niruri Linn. and their pharmacological properties: a review. J Pharm Pharmacol 2006;58(12):1559-70. — PubMed PMID: 17331318 · doi:10.1211/jpp.58.12.0001
  5. Calixto JB, Santos AR, Cechinel Filho V, Yunes RA. A review of the plants of the genus Phyllanthus: their chemistry, pharmacology, and therapeutic potential. Med Res Rev 1998;18(4):225-58. — PubMed PMID: 9664291 · doi:10.1002/(sici)1098-1128(199807)18:4<225::aid-med2>3.0.co;2-x
  6. Srividya N, Periwal S. Diuretic, hypotensive and hypoglycaemic effect of Phyllanthus amarus. Indian J Exp Biol 1995;33(11):861-4. — PubMed PMID: 8786163
  7. Mazumder A, Mahato A, Mazumder R. Antimicrobial potentiality of Phyllanthus amarus against drug resistant pathogens. Nat Prod Res 2006;20(4):323-6. — PubMed PMID: 16644526 · doi:10.1080/14786410600650404 — Antimicrobial work; background on the plant, not a source for uric acid or blood pressure.
  8. Khan MR, Siddique F. Antioxidant effects of Citharexylum spinosum in CCl4 induced nephrotoxicity in rat. Exp Toxicol Pathol 2012;64(4):349-55. — PubMed PMID: 21074979 · doi:10.1016/j.etp.2010.09.009 — A different plant; not a source for any claim on this page.
  9. Bessong PO, Obi CL, Andreola ML, et al. Evaluation of selected South African medicinal plants for inhibitory properties against human immunodeficiency virus type 1 reverse transcriptase and integrase. J Ethnopharmacol 2005;99(1):83-91. — PubMed PMID: 15848024 · doi:10.1016/j.jep.2005.01.056 — Human immunodeficiency virus enzyme work; background only, not a source for uric acid or blood pressure.
  10. Kassuya CA, Silvestre A, Menezes-de-Lima O Jr, Marotta DM, Rehder VL, Calixto JB. Antiinflammatory and antiallodynic actions of the lignan niranthin isolated from Phyllanthus amarus. Evidence for interaction with platelet activating factor receptor. Eur J Pharmacol 2006;546(1-3):182-8. — PubMed PMID: 16925995 · doi:10.1016/j.ejphar.2006.07.025
  11. Adeneye AA, Amole OO, Adeneye AK. Hypoglycemic and hypocholesterolemic activities of the aqueous leaf and seed extract of Phyllanthus amarus in mice. Fitoterapia 2006;77(7-8):511-4. — PubMed PMID: 16905277 · doi:10.1016/j.fitote.2006.05.030
  12. Pucci ND, Marchini GS, Mazzucchi E, Reis ST, Srougi M, Evazian D, Nahas WC. Effect of Phyllanthus niruri on metabolic parameters of patients with kidney stone: a perspective for disease prevention. Int Braz J Urol 2018;44(4):758-764. — PubMed PMID: 29617079
  13. Palmer TM, Nordestgaard BG, Benn M, Tybjaerg-Hansen A, Davey Smith G, Lawlor DA, Timpson NJ. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ 2013;347:f4262. — PubMed PMID: 23869090
  14. White J, Sofat R, Hemani G, et al. Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol 2016;4(4):327-36. — PubMed PMID: 26781229
  15. Juraschek SP, Miller ER 3rd, Gelber AC. Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. Arthritis Care Res 2011;63(9):1295-306. — PubMed PMID: 21671418
  16. Juraschek SP, Gaziano JM, Glynn RJ, Gomelskaya N, Bubes VY, Buring JE, Shmerling RH, Sesso HD. Effects of vitamin C supplementation on gout risk: results from the Physicians' Health Study II trial. Am J Clin Nutr 2022;116(3):812-819. — PubMed PMID: 35575611

PubMed Topic Searches

  1. PubMed: P. niruri xanthine oxidase
  2. PubMed: Phyllanthus hyperuricemia
  3. PubMed: Phyllanthus gout
  4. PubMed: P. amarus hypertension
  5. PubMed: Phyllanthus ACE inhibition
  6. PubMed: geraniin xanthine oxidase
  7. PubMed: uric acid endothelial dysfunction
  8. PubMed: fructose hyperuricemia

Back to Table of Contents

Connections

Back to Table of Contents